Fool.com Headlines http://ift.tt/1D6uOnt Celladon Corp. is nearing a make or break moment in its history with the release of its CUPID-2 top-line data for the cardiovascular gene therapy Mydicar. Here's why this speculative biotech is worth a deeper look by risk-tolerant investors.
No comments:
Post a Comment